Phase III Trial Comparing Surgery Plus Chemotherapy Versus Preoperative Chemoradiotherapy Followed by Surgery Plus Chemotherapy for Locally Recurrent Rectal Cancer
Led by National Cancer Center Hospital East · Updated on 2020-06-04
110
Participants Needed
45
Research Sites
165 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for patients with locally recurrent rectal cancer who have not received prior pelvic radiation. This randomized phase III trial compares the outcomes of two treatment approaches surgery plus adjuvant chemotherapy alone versus preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy. The study aims to confirm whether adding preoperative chemoradiotherapy improves local relapse-free survival, with additional measures including overall survival, relapse rates, surgery success, and quality of life.
Participants are randomly assigned to one of two groups. One group receives preoperative chemoradiotherapy using capecitabine and radiotherapy, followed by surgery and adjuvant chemotherapy, which may include CAPOX, mFOLFOX6, capecitabine, or 5-FU with leucovorin. The other group undergoes surgery followed by the same options for adjuvant chemotherapy. Surgical procedures are performed to achieve complete tumor removal, with timing depending on the assigned treatment arm.
During the study, patients will be monitored at several points including before surgery, after surgery, and up to three years post-registration. Researchers will assess local relapse-free survival, overall survival, relapse-free survival, adverse events, and quality of life. Treatment completion rates and pathological responses to preoperative chemoradiotherapy will also be evaluated. The total duration of follow-up for participants extends through three years after registration to monitor long-term outcomes.
CONDITIONS
Brief Title
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
Research Team
Y
Yuichiro Tsukada, MD,PhD
M
Masaaki Ito, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histopathologically confirmed adenocarcinoma or adenosquamous carcinoma of initial rectal cancer
Initial tumor located in upper, middle, or lower rectum, or anal canal
Initial treatment was surgical or endoscopic resection classified as R0/1 or ER0/1
Patients with distant metastasis treated with radical surgery or radiotherapy more than 168 days before registration are eligible
Recurrent rectal cancer diagnosed pathologically or by multiple imaging methods
Main tumor located within the pelvis or recurrent lesions spreading continuously outside the pelvis
Locally recurrent rectal cancer is resectable with specific conditions met (e.g., no distant metastasis, adequate surgical margins, no leg amputation required)
No prior surgery for recurrent rectal cancer
No prior pelvic irradiation for any malignancy
Final dose of systemic chemotherapy for any malignancy given more than 14 days before registration
Age between 20 and 80 years
Eastern Cooperative Oncology Group performance status 0 or 1
Measurable lesion not mandatory
Adequate oral intake
Sufficient organ function including neutrophils, hemoglobin, platelets, liver enzymes, and creatinine
Planned open or laparoscopic surgery
Written informed consent obtained
You will not qualify if you...
Malignancies within 5 years except those with very high survival rates
Infections requiring systemic treatment
Body temperature over 38 degrees Celsius at registration
Pregnant or lactating women; men with partners planning conception soon
Severe psychological disorders
Ongoing systemic corticosteroid or immunosuppressant therapy
Uncontrolled diabetes or hypertension
Unstable angina or recent myocardial infarction within 6 months
Uncontrolled heart valve disease or cardiomyopathy
Positive Hepatitis B, Hepatitis C, or HIV tests
Interstitial pneumonia, pulmonary fibrosis, or severe emphysema on chest CT
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Preoperative Chemoradiotherapy
Duration - Approximately 5 to 6 weeks
Participants in Arm A receive preoperative chemoradiotherapy with capecitabine and radiotherapy before surgery.
Daily sessions of radiotherapy over about 5 weeks with concurrent medication
Surgery
Duration - Up to 42 days from registration for Arm B or 56 to 98 days after preoperative chemoradiotherapy completion for Arm A
Participants undergo surgery for locally recurrent rectal cancer aiming for complete tumor removal.
1 surgical hospitalization
Adjuvant Chemotherapy
Duration - Up to 8 months after surgery
Participants receive adjuvant chemotherapy post-surgery using CAPOX, mFOLFOX6, capecitabine, or 5-FU+l-LV regimens.
Multiple chemotherapy cycles as per regimen schedule
Follow-up
Duration - Up to 3 years after registration
Participants are monitored for survival, relapse, adverse events, and quality of life after completing treatment.
Regular follow-up visits during 3 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase II Study of Pencil Beam Proton Therapy for Treating Pelvic Recurrences in Adults with Previously Irradiated Rectal Cancer
Phase III Trial Comparing Surgery Plus Chemotherapy Versus Preoperative Chemoradiotherapy Followed by Surgery Plus Chemotherapy for Locally Recurrent Rectal Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study).
A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancer: Japan Clinical Oncology Group study JCOG1801 (RC-SURVIVE study).